



# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated 25/10/2021

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY STANDALONE FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To,

The Board of Directors of  
ANG Lifesciences India Limited.

We have reviewed the accompanying statement of unaudited standalone financial results of **ANG Lifesciences India Limited for the half year ended September 30, 2021**, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on or review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as Amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.



For Raman Wadhwa & Co.  
Chartered Accountants

(Ishant Sharma)

Partner

Regn No. 012036N

M. No. 527055

Place : Amritsar

Date: 25-10-2021

UDIN : 21527055 AAAAGM7806



ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

**STANDALONE FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 30th SEPTEMBER, 2021**

Particulars	Half Year Ended		Previous Year Ended	
	30.09.2021	31.03.2021	30.09.2020	31.03.2021
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	20568.045	6825.141	8612.755	15437.896
II. Other income	13.272	12.749	42.838	55.587
III. Total Revenue (I + II)	20581.317	6837.890	8655.593	15493.483
IV. Expenses:				
(a) Cost of materials consumed	12186.229	4854.589	5971.341	10825.930
(b) Changes in Inventories	657.483	-566.534	136.657	-429.877
(c) Employee benefits expense	828.252	763.677	603.887	1367.564
(d) Finance costs	193.517	154.319	142.250	296.569
(e) Depreciation and amortization expense	139.477	75.335	56.348	131.683
(f) Other expenses	2114.598	1277.390	1010.317	2287.707
Total expenses	16119.555	6558.775	7920.800	14479.575
V. Profit before exceptional and extraordinary items and tax (III-IV)	4461.762	279.115	734.793	1013.908
VI. Exceptional items	0.000	0.000	0.000	0.000
VII. Profit before extraordinary items and tax (V - VI)	4461.762	279.115	734.793	1013.908
VIII. Extraordinary Items	0.000	0.000	0.000	0.000
IX. Profit before tax (VII- VIII)	4461.762	279.115	734.793	1013.908
X Tax expense:		0.000		
(1) Current tax	1060.000	132.900	185.100	318.000
(2) Deferred tax	56.796	-6.330	-0.525	-6.855
(3) Mat Credit Entitlement	0.000	0.000	0.000	0.000
XI Profit (Loss) for the period from continuing operations (VII-VIII)	3344.966	152.545	550.218	702.763
XII Profit/(loss) from discontinuing operations	0.000	0.000	0.000	0.000
XIII Tax expense of discontinuing operations	0.000	0.000	0.000	0.000
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.000	0.000	0.000	0.000



XV	Profit (Loss) for the period (XI + XIV)	3344.966	152.545	550.218	702.763
XVI	Earnings per equity share:				
	(a) Basic & Diluted (Rs.)	64.53	2.943	10.62	13.56
	(b) Diluted (Rs.)	64.53	2.943	10.62	13.56

**Notes :**

- 1) The Audit Committee has reviewed these results and the Board of Directors have approved the above results at their meeting held on October 25, 2021
- 2) As the Company's business activities falls with in a single segment, the disclosure requirement of the Accounting Standard AS(17) "Segment Reporting" as notified under Section 133 of the Companies Act, 2013 read with Rule7 of the Companies (Accounts) Rules 2014 are not applicable.
- 3) The figures for the corresponding previous period have been regrouped/ reclassified wherever considered necessary to confirm the figures in the current period.
- 4) The Figures for the half year ended 31st March 2021 are the balancing figures between the audited figures in respect of the full financial year and the half year ended on 30th September 2020.
- 5) As per MCA Notification dated 16.02.2015, companies whose shares are listed on SME exchange as referred in ChapterXB of SEBI(Issue of Capital Disclosure requirements) regulations 2009 are exempted from the compulsory requirements of adoption of IND-AS. As the company is covered under the exempted category, the company has not adopted IND -AS for preparation of Financials Results.
- 6) There were no Investors complaints pending as on 30.09.2021

For ANG Life Sciences India Limited

**Rajesh  
Gupta**

(Managing Director)

Rajesh Gupta

(DIN : 01423407)

Digitally signed by Rajesh Gupta  
DN: cn=Rajesh Gupta, o=ANG Life Sciences India Limited, email=rajesh.gupta@anglifesciences.com, c=IN  
Date: 2021.10.25 10:10:10 +05'30'

Date : 25.10.2021

Place : Amritsar



ANG Life Sciences India Ltd.  
CIN : L24230PB2006PLC030341  
Registered Office : 113, First Floor, Darbara Complex,  
Ranjit Avenue, Amritsar  
Email ID : cs@anglifesciences.com  
Website : www.anglifesciences.com

STANDALONE STATEMENT OF ASSETS AND LIABILITIES

		(Amount in Lacs)	
Sr. No.	Particulars	For the year ended	For the year ended
		30.09.2021	31.03.2021
I.	<b>EQUITY AND LIABILITIES</b>		
1	Shareholders' funds		
(a)	Share capital	1036.66	518.33
(b)	Reserves and surplus	6466.61	3639.98
	Sub-total-Shareholders' Fund	7503.28	4158.31
2	Non-current liabilities		
(a)	Long-term borrowings	4672.04	702.93
(b)	Other Long-term liabilities	278.57	278.57
(c)	Deferred Tax Liabilities (Net)	80.70	23.90
(d)	Long-term Provisions	67.43	45.26
	Sub-total-non Current Liabilities	5098.73	1050.66
3	Current liabilities		
(a)	Short Term Borrowings	2957.57	3293.87
(b)	Trade Payables		
	Due to Micro, Small & Medium Enterprise	4054.11	885.54
	Due to Others	546.91	3118.49
(c)	Other current liabilities	2335.52	1348.46
(d)	Short-term provisions	1564.70	509.78
	Sub-total-Current Liabilities	11458.81	9156.13
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>24060.81</b>	<b>14365.09</b>
II.	<b>ASSETS</b>		
	Non-current assets		
1	(a) Property, Plant and Equipment		
(i)	Tangible assets	8523.31	2386.49
(ii)	Intangible assets	23.12	23.12
(b)	Other non-current investments	351.94	352.00
(c)	Deferred Tax Assets (Net)	0.00	0.00
(d)	Long-term loans and advances	0.00	0.00
(e)	Other non-current assets	16.79	16.57
	Sub-total-non Current Assets	8915.16	2778.18
2	Current assets		
(a)	Current Investments	0.00	0.00
(b)	Inventories	1997.89	1925.87
(c)	Trade receivables	9534.71	5874.33
(d)	Cash and cash equivalents	430.42	386.30
(e)	Short-term loans and advances	1373.15	2321.68
(f)	Other Current Assets	1809.49	1078.74
	Sub-total-Current Assets	15145.65	11586.91
	<b>TOTAL ASSETS</b>	<b>24060.81</b>	<b>14365.09</b>
	See accompanying notes forming part of the financial statements.		

For ANG Life Sciences India Limited  
**Rajesh Gupta**  
(Managing Director)  
Rajesh Gupta  
(DIN : 01423407)

Date : 25/10/2021  
Place : Amritsar



(In Lacs)

STANDLONE CASH FLOW STATEMENT FOR THE PERIOD ENDED 30th SEPTEMBER, 2021

	Particulars	Year ended 30TH Sept, 2021	Year ended 31st March 2021
(A)	CASH FLOW FROM OPERATING ACTIVITIES		
1	Net Profit/(loss) before extraordinary items and Tax	3344.97	702.76
2	Adjustments for ;		
a)	Depreciation and Amortisation	139.48	131.68
b)	Finance Cost Expenses	193.52	296.57
c)	Current Taxes	1060.00	318.00
d)	Deferred Taxes	56.80	-6.86
e)	Preliminary Expenses	0.00	0.00
f)	MAT Credit	0.00	0.00
	Operating Profit before working capital Changes (1+2)	4794.76	1442.16
3	Adjustments for Working Capital Changes ;		
(i)	(Increase)/decrease Operating Assets		
a)	Trade Receivables	-3660.37	-1267.92
b)	Short Term Loans and Advances	948.54	-1596.54
c)	Other Current Assets	-730.76	-503.61
		0.00	0.00
		0.00	0.00
(ii)	Increase/(Decrease) in Operating Liabilities		
a)	Trade Payables	596.99	1425.06
b)	Short Term Provisions	1060.00	264.70
c)	Other Current Liabilities	981.99	374.74
d)	Other Long Term Liability	0.00	-7.64
e)	Long Term Provisions	22.17	24.95
f)	Short Term Borrowings	-336.30	2001.93
		0.00	0.00
(iii)	(Increase)/Decrease in inventories	-72.02	-925.44
	Less : Income Tax Paid (Net)	3604.99	1232.40
		-1060.00	-318.00
	Net Cash from Operating Activities (A)	2544.99	914.40
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
a)	Purchase of Fixed Assets including Capital W.I.P.	-6276.30	-424.44
b)	Change in Non-Current Assets	-0.22	4.92
c)	Change in Non-Current Investment		0.00
d)	Change in Non-Current Investment		-350.00
	Net Cash from Investing Activities (B)	-6276.52	-769.52
(C)	CASH FLOW FROM FINANCING ACTIVITIES		
a)	Interest paid	-193.52	-296.57
b)	Proceeds from Long Term Borrowings	379.74	395.52
c)	Repayment of Long Term Borrowings	3589.37	-217.59
d)	Proceeds from issue of Share Capital	0.00	0.00
e)	Proceeds from Share Premium	0.00	0.00
f)	Proceeds from sale of assets	0.00	0.00
g)	Decrease in Capital Reserve	0.00	0.00
	Net Cash from Financing Activities (C)	3775.59	-118.64
(D)	Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	44.12	26.24
(E)	Cash & Cash Equivalents at the beginning of the year	386.30	360.05
(F)	Cash & Cash Equivalents at the end of the year	430.42	386.30
Note : 1 Components of Cash & Cash Equivalents			
Cash in hand			
Balance with Schedule Banks			
in Current Accounts			
2. The above Cash Flow Statement has been prepared under the "Indirect Method" as set out in the			
Accounting Standard-3 on Cash Flow Statement issued by the Institute of Chartered Accountants			
of India			
3. The previous year's figures have been regrouped wherever necessary.			

For ANG Life Sciences India Limited

Rajesh Gupta

(Managing Director)

Rajesh Gupta

DIN 01423407

Date : 25/10/2021

Place : Amritsar





# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. 25/10/2021

**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED UNAUDITED HALF YEARLY FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

To,

The Board of Directors of  
ANG Lifesciences India Limited

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Result of **ANG Lifesciences India Limited ("the Parent")** and its subsidiary ( the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit/ (loss) after tax for the half year ended on **30<sup>th</sup> September 2021**, being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure) Regulations, 2015, as amended, to the extent applicable.







# Raman Wadhwa & Co.

CHARTERED ACCOUNTANT

43, 3rd Floor, Nehru Shopping Complex, Lawrence Road, Amritsar.  
E-mail: ishantsharma2187@yahoo.com

Ref. No. ....

Dated. 25/10/2021

4. The Statement includes the results of the following entities:

Mansa Print & Publisher Limited (Subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Amritsar  
Date: 25-10-2021



For Raman Wadhwa & Co.  
Chartered Accounts

(Ishant Sharma)

Partner

Regn no. 012036N

M. NO.527055

UDIN: 21527055AAAA6107984



ANG Life Sciences India Ltd.

CIN : L24230PB2006PLC030341

Registered Office : 113, First Floor, Darbara Complex,

Ranjit Avenue, Amritsar

Email ID : cs@anglifesciences.com, Website : www.anglifesciences.com

**CONSOLIDATED FINANCIAL RESULTS FOR HALF YEAR ENDED AND THE YEAR ENDED 30th SEPTEMBER, 2021**

Particulars	Half Year Ended		Previous Year Ended	
	30.09.2021	31.03.2021	30.09.2020	31.03.2021
	Unaudited	Audited	Unaudited	Audited
I. Revenue from operations	21536.977	6825.141	8612.755	15437.896
II. Other income	17.607	12.750	42.838	55.587
III. Total Revenue (I + II)	21554.584	6837.890	8655.593	15493.483
IV. Expenses:				
(a) Cost of materials consumed	12903.239	4854.589	5971.341	10825.930
(b) Changes in Inventories	543.362	-566.534	136.657	-429.877
(c) Employee benefits expense	936.266	763.677	603.887	1367.564
(d) Finance costs	226.245	154.319	142.250	296.569
(e) Depreciation and amortization expense	172.621	75.335	56.348	131.683
(f) Other expenses	2263.526	1277.390	1010.317	2287.707
Total expenses	17045.258	6558.775	7920.800	14479.575
V. Profit before exceptional and extraordinary items and tax (III-IV)	4509.326	279.115	734.793	1013.908
VI. Exceptional items	0.000	0.000	0.000	0.000
VII. Profit before extraordinary items and tax (V - VI)	4509.326	279.115	734.793	1013.908
VIII. Extraordinary Items	0.000	0.000	0.000	0.000
IX. Profit before tax (VII- VIII)	4509.326	279.115	734.793	1013.908
X Tax expense:		0.000		
(1) Current tax	1060.000	132.900	185.100	318.000
(2) Deferred tax	71.534	-6.330	-0.525	-6.855
(3) Mat Credit Entitlement	0.000	0.000	0.000	0.000
XI Profit (Loss) for the period from continuing operations (VII-VIII)	3377.792	152.545	550.218	702.763
XII Profit/(loss) from discontinuing operations	0.000	0.000	0.000	0.000
XIII Tax expense of discontinuing operations	0.000	0.000	0.000	0.000
XIV Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	0.000	0.000	0.000	0.000



XV	Profit (Loss) for the period (XI + XIV)	3377.792	152.545	550.218	702.763
XVI	Earnings per equity share:				
	(a) Basic & Diluted (Rs.)	32.58	2.943	10.62	13.56
	(b) Diluted (Rs.)	32.58	2.943	10.62	13.56

For ANG Life Sciences India Limited

Rajesh Gupta

(Managing Director)

Rajesh Gupta

(DIN : 01423407)

Date : 25.10.2021

Place : Amritsar



ANG Life Sciences India Ltd.  
CIN : L24230PB2006PLC030341  
Registered Office : 113, First Floor, Darbara Complex,  
Ranjit Avenue, Amritsar  
Email ID : cs@anglifesciences.com  
Website : www.anglifesciences.com

# CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES

(Amount in Lacs)

Sr. No.	Particulars	For the year ended 30.09.2021	For the year ended 31.03.2021
I.	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' funds</b>		
(a)	Share capital	1036.72	518.33
(b)	Reserves and surplus	6467.88	3639.98
	<b>Sub-total-Shareholders' Fund</b>	<b>7504.61</b>	<b>4158.31</b>
2	<b>Non-current liabilities</b>		
(a)	Long-term borrowings	5835.56	702.93
(b)	Other Long-term liabilities	278.57	278.57
(c)	Deferred Tax Liabilities (Net)	80.70	23.90
(d)	Long-term Provisions	70.46	45.26
	<b>Sub-total-non Current Liabilities</b>	<b>6265.29</b>	<b>1050.66</b>
3	<b>Current liabilities</b>		
(a)	Short Term Borrowings	3346.90	3293.87
(b)	Trade Payables		
	Due to Micro, Small & Medium Enterprise	4281.09	885.54
	Due to Others	582.09	3118.49
(c)	Other current liabilities	2803.05	1353.54
(d)	Short-term provisions	1564.70	504.70
	<b>Sub-total-Current Liabilities</b>	<b>12577.83</b>	<b>9156.13</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>26347.73</b>	<b>14365.09</b>
II.	<b>ASSETS</b>		
	<b>Non-current assets</b>		
1 (a)	<b>Property, Plant and Equipment</b>		
(i)	Tangible assets	9402.77	2386.49
(ii)	Intangible assets	23.12	23.12
(b)	Other non-current Investments	2.57	352.00
(c)	Deferred Tax Assets (Net)	398.92	0.00
(d)	Long-term loans and advances	0.00	0.00
(e)	Other non-current assets	18.83	16.57
	<b>Sub-total-non Current Assets</b>	<b>9846.21</b>	<b>2778.18</b>
2	<b>Current assets</b>		
(a)	Current Investments	0.00	0.00
(b)	Inventories	2410.89	1925.87
(c)	Trade receivables	10145.72	5874.33
(d)	Cash and cash equivalents	430.95	386.30
(e)	Short-term loans and advances	1694.98	2321.68
(f)	Other Current Assets	1818.97	1078.74
	<b>Sub-total-Current Assets</b>	<b>16501.52</b>	<b>11586.91</b>
	<b>TOTAL ASSETS</b>	<b>26347.73</b>	<b>14365.09</b>
See accompanying notes forming part of the financial statements.			

For ANG Life Sciences India Limited

Rajesh  
Gupta

(Managing Director)

Rajesh Gupta

(DIN : 01423407)

Date :25.10.2021

Place : Amritsar